CSIMarket Company Name, Ticker, Suppliers, else..
 

Healthcare Sector

In Vitro & In Vivo Diagnostic Substances Industry Growth  


 

Growth Rates by Company within In Vitro & In Vivo Diagnostic Substances Industry

New: More In Vitro & In Vivo Diagnostic Substances Industrys' historic revenue growth >>

 Revenue Growth Net Income Growth
Company Quarter Y / Y Sequential Y / Y Sequential
Achieve Life Sciences Inc 1Q 2025 - - - -
Aspira Women s Health Inc 4Q 2024 down-42.58 % down -49.69 % - -
Biomerica Inc 4Q 2024 up 4.4 % down -9.46 % - -
Burzynski Research Institute Inc 1Q 2025 - - - -
Cardio Diagnostics Holdings Inc 1Q 2025 down-94.1 % down -79.17 % - -
Celldex Therapeutics inc 1Q 2025 up 345.51 % down -40.85 % - -
Heska Corporation 1Q 2023 down-3.73 % down -5.96 % - -
Immucell Corp 1Q 2025 up 28.14 % down -9.92 % - up 181.21 %
Idexx Laboratories Inc 1Q 2025 up 3.56 % up 4.58 % up 3.01 % up 12.27 %
Lantheus Holdings Inc 1Q 2025 up 0.77 % down -4.81 % down -44.34 % -
Myriad Genetics Inc 1Q 2025 down-3.46 % down -7.22 % - -
Navidea Biopharmaceuticals Inc 3Q 2023 - - - -
Neogen Corporation 1Q 2025 down-3.34 % down -4.37 % - -
Intellia Therapeutics Inc 1Q 2025 down-42.54 % up 29.15 % - -
Nymox Pharmaceutical Corporation 4Q 2024 - - - -
Oncocyte Corporation 1Q 2025 up 1114.77 % up 58.96 % - -
Quidelortho Corp 1Q 2025 down-2.56 % down -2.12 % - -
Alpha Teknova Inc 1Q 2025 down-2.19 % down -11.07 % - -
Tnf Pharmaceuticals Inc 3Q 2024 - - - -
Trinity Biotech Plc 4Q 2023 down-24 % down -24 % - -
Volitionrx Limited 1Q 2025 up 43.64 % up 28.56 % - -
Revenue
In Vitro & In Vivo Diagnostic Substances Industry

recorded in the 1. Quarter 2025 above average Revenue deterioration of -98.79 % year on year, Total Ranking #72 and ranking within sector #5.

Sequentially Revenues for In Vitro & In Vivo Diagnostic Substances Industry fell by -91.88 %.

More on In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth




Income
In Vitro & In Vivo Diagnostic Substances Industry
in the 1. Quarter 2025 Net loss contracted year on year.

Sequentially, In Vitro & In Vivo Diagnostic Substances Industry Net loss narrowed from previous quarter.

More on In Vitro & In Vivo Diagnostic Substances Industry Income Growth




• Inc. Cont. Ops.
• Net Income
• EPS Cont. Ops.
• EPS Net
• Free Cash Flow
• Net Cash Flow
• Capex








Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com